Bioxytran Reports Positive Phase 2 Results for ProLectin-M Antiviral

Rapid viral clearance demonstrated in 100% of patients by day 7 versus placebo

Published on Feb. 11, 2026

Got story updates? Submit your updates here. ›

Bioxytran, Inc. announced positive results from a Phase 2 clinical trial evaluating its antiviral drug candidate ProLectin-M in subjects with acute viral infection. The study found complete elimination of viral load in 100% of treated subjects by day 7, compared to placebo. No viral rebounds were observed during the 14-day post-treatment period.

Why it matters

ProLectin-M's novel mechanism of action, which targets viral entry at the cell surface rather than viral replication, represents a fundamentally different approach to antiviral therapy. These results further support the potential of carbohydrate-based therapeutics and the emerging field of Glycovirology to address significant unmet needs in treating viral diseases.

The details

The Phase 2 trial was a randomized, double-blind, placebo-controlled study that enrolled 38 subjects with acute viral infection. Subjects were randomized to receive one of three ProLectin-M dose levels or placebo over a 7-day treatment period. Viral shedding was assessed using RT-PCR, with clearance defined as non-detection of viral RNA. The study demonstrated complete viral elimination in 100% of treated subjects by day 7, compared to placebo (p=.001). No viral rebounds were observed during the 14-day post-treatment observation period.

  • The Phase 2 clinical study was recently completed.
  • Viral clearance was observed as early as day 3, with 16 of 38 subjects demonstrating non-detection of viral shedding by day 5 and 100% of treated subjects clearing the virus by day 7.

The players

Bioxytran, Inc.

A clinical-stage biotechnology company developing novel carbohydrate-based therapeutics, including the lead program ProLectin-M, a potential broad-spectrum antiviral.

Dr. Leslie Ajayi

Chief Medical Officer of Bioxytran.

Dr. David Platt

Chief Executive Officer of Bioxytran.

Got photos? Submit your photos here. ›

What they’re saying

“The study design of seven days reflects real-world applications for treating acute viral diseases, with the objective of demonstrating a statistically meaningful reduction in viral load by Day 7.”

— Dr. Leslie Ajayi, Chief Medical Officer of Bioxytran

“What continues to distinguish ProLectin-M as a broad-range antiviral drug is its novel mechanism of action. Rather than targeting viral replication inside the cell, our galectin antagonist is designed to interfere with viral entry at the cell surface. This extracellular approach may reduce reliance on immune activation and represents a fundamentally different strategy in antiviral therapy.”

— Dr. David Platt, Chief Executive Officer of Bioxytran

What’s next

Based on these results, Bioxytran plans to advance regulatory discussions to support late-stage clinical development and evaluate ProLectin-M across additional viral indications consistent with its broad-spectrum antiviral profile.

The takeaway

ProLectin-M's novel mechanism of action and these positive Phase 2 results demonstrating rapid and sustained viral clearance represent an important advancement in the development of carbohydrate-based antiviral therapies that could address significant unmet needs in treating viral diseases.